Literature DB >> 7921857

Use of esmolol to prevent hemodynamic changes during intubation in general anesthesia.

S C Wang1, C C Wu, M S Lin, C F Chang.   

Abstract

To assess the minimal effective dosage of esmolol to prevent hypertension and tachycardia during laryngoscopy and endotracheal intubation in fentanyl-pretreated anesthesia, a double-blinded, randomized study was conducted. Two hundred patients undergoing elective, noncardiac surgeries were randomly allocated into four groups: group A received saline, group B esmolol 20 mg, group C esmolol 40 mg and group D esmolol 60 mg intravenously. General anesthesia was induced with 0.1 mg/kg vecuronium, 5 micrograms/kg fentanyl and 0.3 mg/kg etomidate. Heart rates (HR), systolic blood pressures (SBP), mean arterial pressures (MAP) and diastolic blood pressures (DBP) were recorded before induction, after induction, before intubation, 30 seconds, 1 minute, 2 minutes, 4 minutes, 6 minutes, and 10 minutes after intubation. After intubation HR and SBP increased significantly in group A (86.7 beats/min, 166.6 mmHg) in comparison with groups C (77.6 beats/min, 153.9 mmHg) and D (73.4 beats/min, 153.4 mmHg) (p < 0.05). Tachycardia (HR > 100) was found in 13 of 50(26%) patients in group A, 10 of 50(20%) patients in group B, 7 of 50(14%) patients in group C and 2 of 50(4%) patients in group D. Hypertension (SBP > 180) was found in 18(36%) patients in group A, 19(38%) patients in group B, 9(18%) patients in group C, and 6(12%) patients in group D. When compared with group A, only group D had significantly lower incidence of these adverse events (p < 0.05). In conclusion, fentanyl 5 micrograms/kg could not completely prevent the hemodynamic changes associated with endotracheal intubation, and 60 mg esmolol was observed to have positive effect in helping to control these changes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7921857

Source DB:  PubMed          Journal:  Acta Anaesthesiol Sin        ISSN: 0254-1319


  4 in total

1.  Perioperative beta-blockers for preventing surgery-related mortality and morbidity in adults undergoing non-cardiac surgery.

Authors:  Hermann Blessberger; Sharon R Lewis; Michael W Pritchard; Lizzy J Fawcett; Hans Domanovits; Oliver Schlager; Brigitte Wildner; Juergen Kammler; Clemens Steinwender
Journal:  Cochrane Database Syst Rev       Date:  2019-09-26

2.  Landiolol attenuates the cardiovascular response to tracheal intubation.

Authors:  Toru Goyagi; Makoto Tanaka; Toshiaki Nishikawa
Journal:  J Anesth       Date:  2005       Impact factor: 2.078

3.  Landiolol attenuates cardiovascular response at induction of general anesthesia for cesarean delivery.

Authors:  Koichi Suehiro; Ryu Okutani
Journal:  J Anesth       Date:  2011-12-17       Impact factor: 2.078

4.  Effect of low-dose landiolol, an ultrashort-acting beta-blocker, on postoperative atrial fibrillation after CABG surgery.

Authors:  Hidenori Fujiwara; Masahiro Sakurai; Asako Namai; Takae Kawamura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-03-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.